MI-773 (SAR405838)CAS# 1303607-60-4 |
Related Products
- MTEP hydrochloride
Catalog No.:BCC1780
CAS No.:1186195-60-7
- LY341495
Catalog No.:BCC1724
CAS No.:201943-63-7
- MPEP Hydrochloride
Catalog No.:BCC1777
CAS No.:219911-35-0
- CPPHA
Catalog No.:BCC1501
CAS No.:693288-97-0
- Dipraglurant
Catalog No.:BCC1531
CAS No.:872363-17-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1303607-60-4 | SDF | Download SDF |
| PubChem ID | 53476877 | Appearance | Powder |
| Formula | C29H34Cl2FN3O3 | M.Wt | 562.50 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | MI-77301 | ||
| Solubility | DMSO : ≥ 50 mg/mL (88.89 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (2'R,3R,3'S,5'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-N-(4-hydroxycyclohexyl)-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide | ||
| SMILES | CC(C)(C)CC1C2(C(C(N1)C(=O)NC3CCC(CC3)O)C4=C(C(=CC=C4)Cl)F)C5=C(C=C(C=C5)Cl)NC2=O | ||
| Standard InChIKey | IDKAKZRYYDCJDU-AEPXTFJPSA-N | ||
| Standard InChI | InChI=1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)/t16?,17?,22-,23-,25+,29+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | SAR405838 is a highly potent and selective MDM2 inhibitor, binds to MDM2 with Ki= 0.88 nM and has high specificity over other proteins.
IC50 value: 0.88 nM (Ki) [1]
Target: MDM2
in vitro: SAR405838 potently inhibits cell growth in cancer cell lines, including SJSA-1 (IC50, 0.092 μM), RS4;11 (IC50, 0.089 μM), LNCaP (IC50, 0.27 μM), and HCT-116 (IC50, 0.20 μM) cells, and displays high selectivity over cancer cell lines with mutated or deleted p53, including SAOS-2 (IC50, >10 μM), PC-3 (IC50, >10 μM), SW620 (IC50, >10 μM), and HCT-116 (p53-/-) (IC50, >20 μM) cells.[1] SAR405838 effectively induces apoptosis in the RS4;11 cell line. SAR405838 potently inhibits cell growth and induces dose-dependent apoptosis in the ABTR1 and ABTR2 sublines, albeit with modestly reduced potency compared with that in the control RS4;11 cell line.[2]
in vivo: At well-tolerated dose schedules, SAR405838 achieves either durable tumor regression or complete tumor growth inhibition in mouse xenograft models of SJSA-1 osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer and HCT-116 colon cancer. Remarkably, a single oral dose of SAR405838 is sufficient to achieve complete tumor regression in the SJSA-1 model. In the SJSA-1 osteosarcoma, acute lymphoblastic leukemia RS4;11, LNCaP prostate cancer, and HCT-116 colon cancer xenograft model, MI-773 (p.o.) effectively inhibits tumor growth in a dose-dependent manner (10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg,). [1] References: | |||||
MI-773 (SAR405838) Dilution Calculator
MI-773 (SAR405838) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7778 mL | 8.8889 mL | 17.7778 mL | 35.5556 mL | 44.4444 mL |
| 5 mM | 0.3556 mL | 1.7778 mL | 3.5556 mL | 7.1111 mL | 8.8889 mL |
| 10 mM | 0.1778 mL | 0.8889 mL | 1.7778 mL | 3.5556 mL | 4.4444 mL |
| 50 mM | 0.0356 mL | 0.1778 mL | 0.3556 mL | 0.7111 mL | 0.8889 mL |
| 100 mM | 0.0178 mL | 0.0889 mL | 0.1778 mL | 0.3556 mL | 0.4444 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
Featured Products
- MI-773
Catalog No.:BCC5155
CAS No.:1303607-07-9
- Cathayanon I
Catalog No.:BCN3678
CAS No.:1303438-52-9
- Cathayanon H
Catalog No.:BCN3570
CAS No.:1303438-51-8
- CI 988
Catalog No.:BCC7430
CAS No.:130332-27-3
- H-D-Phe-OMe.HCl
Catalog No.:BCC3013
CAS No.:13033-84-6
- Fmoc-Oic-OH
Catalog No.:BCC3305
CAS No.:130309-37-4
- Fmoc-D-Tic-OH
Catalog No.:BCC3342
CAS No.:130309-33-0
- HOE 140
Catalog No.:BCC5964
CAS No.:130308-48-4
- Fmoc-Asp(OcHex)-OH
Catalog No.:BCC3468
CAS No.:130304-80-2
- Rubiarbonol B
Catalog No.:BCN6159
CAS No.:130288-60-7
- PD 135158
Catalog No.:BCC7431
CAS No.:130285-87-9
- 3'-Demethoxypiplartine
Catalog No.:BCN4021
CAS No.:130263-10-4
New Products
- AC 45594
Catalog No.:BCC7544
CAS No.:13037-86-0
- Batimastat (BB-94)
Catalog No.:BCC1223
CAS No.:130370-60-4
- Decinnamoyltaxagifine
Catalog No.:BCN7329
CAS No.:130394-69-3
- Pungiolide A
Catalog No.:BCN8128
CAS No.:130395-54-9
- 2-Oxokolavenol
Catalog No.:BCN4716
CAS No.:130395-82-3
- DL-AP5 Sodium salt
Catalog No.:BCC7753
CAS No.:1303993-72-7
- CHPG Sodium salt
Catalog No.:BCC7755
CAS No.:1303993-73-8
- (RS)-MCPG disodium salt
Catalog No.:BCC7756
CAS No.:1303994-09-3
- Paulownin
Catalog No.:BCN6160
CAS No.:13040-46-5
- (-)-Catechin gallate(CG)
Catalog No.:BCN5330
CAS No.:130405-40-2
- A-71623
Catalog No.:BCC7354
CAS No.:130408-77-4
- Peucedanocoumarin I
Catalog No.:BCN3434
CAS No.:130464-55-0
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.[Pubmed:27764791]
Oncotarget. 2016 Dec 13;7(50):82757-82769.
Neuroblastoma (NB), which accounts for about 15% of cancer-related mortality in children, is the most common childhood extracranial malignant tumor. In NB, somatic mutations of the tumor suppressor, p53, are exceedingly rare. Unlike in adult tumors, the majority of p53 downstream functions are still intact in NB cells with wild-type p53. Thus, restoring p53 function by blocking its interaction with p53 suppressors such as MDM2 is a viable therapeutic strategy for NB treatment. Herein, we show that MDM2 inhibitor SAR405838 is a potent therapeutic drug for NB. SAR405838 caused significantly decreased cell viability of p53 wild-type NB cells and induced p53-mediated apoptosis, as well as augmenting the cytotoxic effects of doxorubicin (Dox). In an in vivo orthotopic NB mouse model, SAR405838 induced apoptosis in NB tumor cells. In summary, our data strongly suggest that MDM2-specific inhibitors like SAR405838 may serve not only as a stand-alone therapy, but also as an effective adjunct to current chemotherapeutic regimens for treating NB with an intact MDM2-p53 axis.
SAR405838 is a highly potent and selective MDM2 inhibitor, binds to MDM2 with Ki= 0.88 nM and has high specificity over other proteins.
MI-773 (SAR405838),1303607-60-4,MI-77301,Natural Products,MDM2, buy MI-773 (SAR405838) , MI-773 (SAR405838) supplier , purchase MI-773 (SAR405838) , MI-773 (SAR405838) cost , MI-773 (SAR405838) manufacturer , order MI-773 (SAR405838) , high purity MI-773 (SAR405838)
